PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH

PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH Whenever we are asked to contribute a patient group submission about a hepatitis-C or hepatitis-B related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Below are the submissions we have made, from

PATIENTS, CAREGIVERS: HepCBC NEEDS YOUR INPUT RE: SIMEPREVIR

Simeprevir (trade name GALEXOS™, produced by Janssen, Inc.) was recently approved for use in Canada to treat hepatitis C, but BC PharmaCare doesn't cover it yet. Like similar drugs telaprevir/INCIVEK™ and boceprevir/VICTRELIS™, simeprevir is generally given to genotype 1 patients for several weeks in combination with two other medications (hence the name, "Triple Therapy"). In Triple Therapy with simeprevir, the drug is taken once a day (one pill) along wi